Recce Pharmaceuticals has developed a new class of synthetic antibiotics. These new compounds have demonstrated safety and efficacy in a range of pre-clinical tests to destroy a number of prevalent antibiotic resistant bacteria.
Our lead compound, RECCE® 327, has demonstrated positive activity against a broad range of Multi-Drug Resistant Gram-negative and Gram-positive bacterial infections.
- Commercial antibiotics are naturally derived – superbugs to them have been forming for millenniums – and will continue to do so.
- Designed with a purpose, RECCE®327 contains millions of monomers, specially chosen for their desired characteristics and then proprietarily bound together to form powerful polymers – not reliant on what was found in nature.
- RECCE® 327 is wholly synthetic and works by adhering to the outer membrane of the deadly bacteria, breaking down the proteins in a non-specific way, causing the bacterial cell to burst.
- Designed to be attracted to the unique ‘lipid’ outer-membranes of all bacteria, regardless of Gram stain, or mutation – it’s just bacteria to us.
While our main focus is on the development of RECCE® 327 for sepsis, we have a number of other product candidates under development which seeks to exploit the unique capabilities of RECCE® technologies across synergistic ‘urgent’ human health conditions.
There have been no new classes of antibiotics on the market for over 30 years - Recce® 327 has the potential to break that mould. Recce 327® is a synthetic polymer, designed to target bacteria that cause infectious disease – including ones that are resistant to current antibiotics – the superbugs. Bacterial infections of the blood are deadly and affect an estimated 30 million people world-wide every year - this is where Recce® 327 is designed to act. Recce® 327 is designed to be administered through injection so it can quickly spread through the blood stream.
Recce® 327 is designed to adhere to the outer cell wall of the infectious bacteria through hydrophobic interactions. This weakens the cell wall and internal pressures from within the cell cause the bacteria to burst. The body’s own mechanisms can then clear the infection. Normal non-bacterial cells remain intact as they do not contain high internal pressures.
Tests have shown Recce® 327 is fast acting and as a broad spectrum antibiotic is effective against gram positive and gram negative bacteria including antibiotic resistant superbugs. Following regulatory requirements for new antibiotics, safety and efficacy tests will continue to urgently explore Recce® 327’s ability to address the global threat posed by superbugs. Together we can make antibiotic resistance history – visit recce.com.au to find out more.